SCHEMBL3409162

SCHEMBL3409162

CC1(C)Oc2ccccc2C(N)C1Cl

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNE1 P15382 1/20 0.38
KCNQ1 P51787 1/20 0.38
LMNA P02545 2/20 0.35
ABCB1 P08183 1/20 0.33
KMT2A Q03164 1/20 0.31
ALDH1A1 P00352 2/20 0.31
GAA P10253 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
HTR2B P41595 1/20 0.31
HTR2A P28223 2/20 0.31
MAOA P21397 1/20 0.31
MAOB P27338 1/20 0.31
KDM4E B2RXH2 1/20 0.30
APOBEC3A P31941 1/20 0.30
APOBEC3G Q9HC16 1/20 0.30
ATM Q13315 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9354158 0.80 KCNE1 (0.49) KCNE1KCNQ1ABCB1L3MBTL1MAOA
SCHEMBL29172252 0.80 KCNE1 (0.49) KCNE1KCNQ1ABCB1L3MBTL1MAOA
SCHEMBL7797206 0.80 KCNE1 (0.49) KCNE1KCNQ1ABCB1L3MBTL1MAOA
SCHEMBL29653950 0.80 KCNE1 (0.49) KCNE1KCNQ1ABCB1L3MBTL1MAOA
SCHEMBL29653960 0.80 KCNE1 (0.49) KCNE1KCNQ1ABCB1L3MBTL1MAOA
SCHEMBL9354152 0.80 KCNE1 (0.49) KCNE1KCNQ1ABCB1L3MBTL1MAOA
Hydrochloric Acid SCHEMBL11610839 0.79 KCNE1 (0.48) KCNE1KCNQ1ABCB1L3MBTL1MAOA
Hydrochloric Acid SCHEMBL11610828 0.79 KCNE1 (0.48) KCNE1KCNQ1ABCB1L3MBTL1MAOA
Hydrochloric Acid SCHEMBL11610843 0.79 KCNE1 (0.48) KCNE1KCNQ1ABCB1L3MBTL1MAOA
SCHEMBL24151289 0.77 KCNE1 (0.42) KCNE1KCNQ1LMNAABCB1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8487121-B2 Chromane derivatives as TRPV3 modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2013-07-16 US disclosed
US-20100311778-A1 CHROMANE DERIVATIVES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2010-12-09 US disclosed
EP-2254879-A2 CHROMANE DERIVATIVES AS TRPV3 MODULATORS Glenmark Pharmaceuticals S.A. (CH) 2010-12-01 EP disclosed
WO-2009084034-A2 CHROMANE DERIVATIVES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS, S. A. (CH) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311778-A1 CHROMANE DERIVATIVES AS TRPV3 MODULATORS TRPV3, TRPV2, TRPV1 KCNE1 214/4885KCNQ1 449/4885LMNA 1576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.